Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial-Reference-Cited by-同舟云学术

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

Published:2021-05 Issue:5 Volume:16 Page:860-867
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Faivre-Finn Corinne,Vicente David,Kurata Takayasu,Planchard David,Paz-Ares Luis,Vansteenkiste Johan F.,Spigel David R.,Garassino Marina C.,Reck Martin,Senan Suresh,Naidoo Jarushka,Rimner Andreas,Wu Yi-Long,Gray Jhanelle E.,Özgüroğlu Mustafa,Lee Ki H.,Cho Byoung C.,Kato Terufumi,de Wit Maike,Newton Michael,Wang Lu,Thiyagarajah Piruntha,Antonia Scott J.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. Therapeutic management options for stage III non-small cell lung cancer;Yoon;World J Clin Oncol,2017

2. Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non–small-cell lung cancer;Bradley;J Clin Oncol,2020

3. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer;Senan;J Clin Oncol,2016

4. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology;Hanna;J Clin Oncol,2008

5. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody;Stewart;Cancer Immunol Res,2015

Cited by 340 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic modification in radiotherapy and immunotherapy for cancers;Tzu Chi Medical Journal;2024-09-05

2. Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy;Biomarker Research;2024-09-04

3. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database;Journal of Geriatric Oncology;2024-09

4. Stellenwert einer „targeted therapy“ beim EGFR-mutierten Lungenkarzinom nach erfolgter Radiochemotherapie;Strahlentherapie und Onkologie;2024-08-02

5. A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA–B GFPC 04-2020Study);Lung Cancer;2024-08